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Search Strategy:

1 Hyperparathyroidism, Primary/dt \[Drug Therapy\] (99)

2 Hyperparathyroidism, Primary/(2211)

3 Parathyroid adenom\*.mp. (4188)

4 (Primary adj2 Hyperparathyr\*).mp. (9043)

5 2 or 3 or 4 (11256)

6 exp Diphosphonates/(22931)

7 bisphosphonate\*.mp. (14211)

8 diphosphonat\*.mp. (17321)

9 bisphosphonic\*.mp. (152)

10 clodron\*.mp. (2326)

11 alendron\*.mp. (4714)

12 etidron\*.mp. (3123)

13 ibandron\*.mp. (1063)

14 incadron\*.mp. (78)

15 medron\*.mp. (4405)

16 minodron\*.mp. (104)

17 neridron\*.mp. (94)

18 olpadron\*.mp. (77)

19 pamidron\*.mp. (2920)

20 risedron\*.mp. (1775)

21 tiludron\*.mp. (156)

22 zoledron\*.mp. (4145)

23 cinacalcet.mp. (1071)

24 Cinacalcet Hydrochloride/(735)

25 \"amg 073\".mp. (24)

26 amg073.mp. (0)

27 krn 1493.mp. (3)

28 krn1493.mp. (4)

29 mimpara.mp. (20)

30 parareg.mp. (0)

31 regpara.mp. (1)

32 sensipar.mp. (30)

33 exp Isoflavones/(15928)

34 ipriflavone.mp. (268)

35 Denosumab/(925)

36 denosumab.mp. (1712)

37 amg 162.mp. (33)

38 amg162.mp. (3)

39 amgiva.mp. (0)

40 prolia.mp. (32)

41 xgeva.mp. (16)

42 blosozumab.mp. (14)

43 ly 2541546.mp. (0)

44 ly2541546.mp. (1)

45 romosozumab.mp. (45)

46 amg 785.mp. (27)

47 amg785.mp. (0)

48 cdp 7851.mp. (0)

49 cdp7851.mp. (3)

50 odanacatib.mp. (156)

51 (\"mk 0822\" or mk0822 or mk822 or mk 822).mp. (5)

52 etelcalcetide.mp. (5)

53 (amg 416 or amg416).mp. (12)

54 (kai 4169 or kai4169).mp. (1)

55 (ono 5163 or ono5163).mp. (0)

56 telcalcetide.mp. (0)

57 velcalcetide.mp. (4)

58 or/6-57 (49081)

59 5 and 58 (459)

60 1 or 59 (491)
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